Table 2 Treatments and outcomes of patients in the COVID-19 and control groups*
|  | Total (n = 105) | Control (n = 40) | COVID-19 (n = 65) | P Value |
|---|---|---|---|---|
Treatment | Â | Â | Â | Â |
Intranasal steroid | Â | Â | Â | 0.608 |
 No | 40 (38.1) | 14 (35) | 26 (40) |  |
 Yes | 65 (61.9) | 26 (65) | 39 (60) |  |
Nasal decongestant | Â | Â | Â | 0.029 |
 No | 54 (51.4) | 26 (65) | 28 (43.1) |  |
 Yes | 51 (48.6) | 14 (35) | 37 (56.9) |  |
Mucolytic | Â | Â | Â | 0.281 |
 No | 41 (39.0) | 13 (32.5) | 28 (43.1) |  |
 Yes | 64 (61.0) | 27 (67.5) | 37 (56.9) |  |
Oral antibiotic | Â | Â | Â | 0.325 |
 No | 90 (85.7) | 36 (90) | 54 (83.1) |  |
 Yes | 15 (14.3) | 4 (10) | 11 (16.9) |  |
Oral steroid | Â | Â | Â | 0.404 |
 No | 99 (94.3) | 39 (97.5) | 60 (92.3) |  |
 Yes | 6 (5.7) | 1 (2.5) | 5 (7.7) |  |
Topical steroid | Â | Â | Â | 0.295 |
 No | 101 (96.2) | 40 (100) | 61 (93.8) |  |
 Yes | 4 (3.8) | 0 (0) | 4 (6.2) |  |
Topical antibiotic | Â | Â | Â | 1 |
 No | 100 (95.2) | 38 (95) | 62 (95.4) |  |
 Yes | 5 (4.8) | 2 (5) | 3 (4.6) |  |
Tympanocentesis | Â | Â | Â | 0.02 |
 No | 52 (49.5) | 14 (35) | 38 (58.5) |  |
 Yes | 53 (50.5) | 26 (65) | 27 (41.5) |  |
Outcome |  |  |  | < 0.001 |
 Complete resolution | 54 (51.4) | 12 (30) | 42 (64.6) |  |
 Improvement | 27 (25.7) | 7 (17.5) | 20 (30.8) |  |
 Persistence | 24 (22.9) | 21 (52.5) | 3 (4.6) |  |